Refine results:

Clear all

Healthcare workers taking patients' details.

Opinion | 13 October 2020

Once we have effective Covid-19 treatments, it shouldn’t only be the rich who benefit by Jeremy Farrar

We need a range of treatments to make Covid-19 preventable and treatable. Jeremy Farrar describes recent progress made by research and why more investment is needed.

A mother and child's body temperatures are being tested at the gate of entry upon arrival at the Murtala International Airport in Lagos.

Opinion | 12 October 2020

More people should have access to monoclonal antibodies. Covid-19 can make that happen by Lindsay Keir

Monoclonal antibodies, one of the most promising treatments for Covid-19, are usually expensive and not available worldwide. Lindsay Keir highlights what needs to be done to change that.

Illustration of a magnifying glass over a person speaking to another person

Opinion | 5 October 2020

To make the charity sector safe for everyone, we need to Speak Up by Fraser Simpson

We know that in the charity sector it can be difficult for colleagues to challenge bad practice. That’s why we’ve developed Speak Up – a new initiative to help us build a real culture of trust.

Two nurses talk in a hospital.

Explainer | 5 October 2020

What are monoclonal antibodies – and can they treat Covid-19?

For more than 30 years, monoclonal antibodies have transformed the way we treat many diseases. Researchers think they are also one of the most promising treatments for Covid-19. Here's why.

Shoppers walking on a street where coronavirus signs are visible.

Opinion | 28 September 2020

Covid-19 in the UK: the hard choices we face by Jeremy Farrar

Six months after lockdown was first announced in the UK, the country is seeing a rise in Covid-19 infections. Jeremy Farrar reflects on the measures we need to suppress transmission.

People wearing protective masks stand on the steps of the Metropolitan Museum of Art in New York which displays a banner with the word 'together'.

Opinion | 28 September 2020

What’s next for COVID-Zero? by Mark Henderson

Wellcome launched COVID-Zero in April to mobilise urgent donations from businesses and philanthropists for Covid-19 research. As we draw the campaign to a close, Mark Henderson discusses what it has achieved.

Animation showing a doctor administering a vaccine to a volunteer

Explainer | 25 September 2020

What are human infection studies and why do we need them?

Human infection studies have the power to rapidly accelerate the development of much-needed vaccines and treatments, including for Covid-19.

A volunteer offers a passer-by a face mask.

Opinion | 24 September 2020

Covid-19: what’s good for public health is also good for the economy by Claude Lopez

Covid-19 is exacerbating existing health, economic and social inequalities in the US and across the world. Claude Lopez explains why investing in coronavirus treatment research and development is an imperative for business leaders and philanthropists.

A teacher wearing a mask speaks to her students in front of the classroom.

Explainer | 23 September 2020

From equality to global poverty: how Covid-19 is affecting societies and economies

The Covid-19 pandemic is a social and an economic crisis just as much as it is a health crisis – its repercussions, severe and far-reaching, are being felt across the world.

A worker cleans the exterior of a train coach that has been converted into a Covid-19 isolation ward.

Opinion | 16 September 2020

Could Covid-19 be fuelling drug resistance? by Gemma Buckland Merrett

We need to understand the impact of Covid-19 on wider health issues to shape better public health responses and limit long-term consequences. Drug resistance is one of these, Gemma Buckland-Merrett explains.

A woman walks inside a clinical trials centre, in front of a sign which reads Covid-19 vaccine trials here

Explainer | 11 September 2020

Safety first: how to run a Covid-19 vaccine clinical trial

The world is waiting eagerly for Covid-19 vaccines to be developed as quickly as possible. But to make sure they are safe and effective, the clinical trials that test them have to be robust. So how do trials achieve this?

A nurse wearing a face mask and a vaccine trial volunteer sitting in an observation room in a repurposed convention centre in Manama, Bahrain.

Opinion | 7 September 2020

The first Covid-19 vaccine may not be the magic bullet that returns life to 'normal' by Jeremy Farrar

As we'll soon start to see the results of the first vaccines coming through late-stage clinical trials, Jeremy Farrar explains why we should be cautiously optimistic.